DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Biden - 3 Sanofi - 2 Nirsevimab - 2 there's - 1 Beyfortus - 1 Infants - 1 Palivizumab - 1
Top related locs:
U.S United States Nirsevimab French England Canada Europe United Kingdom
Top related orgs:
AstraZeneca - 4 Sanofi - 4 Drug Administration - 3 Children - 3 Centers for Disease Control - 2 CDC - 2 FDA - 2 U.S . Food - 1

Search resuls for: "Palivizumab"


5 mentions found


☆ A New RSV Shot for Infants Is in Short Supply
  + stars: | 2023-10-24 | by ( Associated Press | Oct. | At A.M. | ) www.usnews.com   time to read: +2 min
NEW YORK (AP) — A new shot for infants against RSV is in short supply, and U.S. health officials told doctors they should prioritize giving the drug to babies at the highest risk of severe disease. The larger doses are for larger, heavier infants. Supply of the smaller doses also may be limited during the current RSV season, CDC officials said. The CDC said doctors should not use two smaller doses on larger infants, so as to preserve the supply of those shots. Some children may be eligible for an older RSV drug, palivizumab, agency officials said.
Persons: Sanofi, there's Organizations: Centers for Disease Control, AstraZeneca, Sanofi, U.S . Food, Drug Administration, CDC, Associated Press Health, Science Department, Howard Hughes Medical Institute’s Science, Educational Media Group, AP Locations: U.S, United States
☆ Sanofi expects infant RSV shot to roll out before respiratory virus season this fall
  + stars: | 2023-07-21 | by ( Spencer Kimball | ) www.cnbc.com   time to read: +2 min
Sanofi expects its infant RSV shot to roll out in the U.S. before respiratory virus season this fall, a company spokesperson said Friday. The Food and Drug Administration on Monday approved Beyfortus, a monoclonal antibody that is administered as a single dose to infants before or during their first respiratory syncytial virus season. The Sanofi spokesperson said the company does not expect any challenges with manufacturing or capacity to meet demand this RSV season. Sanofi is working with the panel to place Beyfortus on the U.S. childhood immunization schedule, the company spokesperson said. Nearly 100 infants die every year in the U.S. from the virus, according to a study last year.
Persons: Sanofi, Beyfortus, Biden Organizations: Drug Administration, Sanofi, AstraZeneca, Centers for Disease Control, Children Locations: U.S, French, England
☆ FDA approves AstraZeneca, Sanofi shot that protects infants and toddlers against RSV
  + stars: | 2023-07-17 | by ( Spencer Kimball | ) www.cnbc.com   time to read: +3 min
The FDA approval of nirsevimab, sold under the brand name Beyfortus, comes ahead of RSV season this fall. This is a major advantage over palivizumab, which is administered monthly throughout RSV season. Nirsevimab is administered either before or during an infant's first RSV season. Toddlers up to two years old who remain vulnerable can also receive the shot during their second RSV season. Pfizer has developed a vaccine that protects infants by administering the shot to the mother while she is pregnant.
Persons: Biden, Nirsevimab Organizations: Drug Administration, AstraZeneca, Sanofi, FDA, Disease Control, Children, CDC, Pfizer Locations: U.S, Nirsevimab
☆ FDA advisors recommend AstraZeneca, Sanofi antibody to protect babies from RSV
  + stars: | 2023-06-08 | by ( Spencer Kimball | ) www.cnbc.com   time to read: +2 min
If the FDA approves nirsevimab, the antibody would become the first medical intervention available in the U.S. that can protect all infants from RSV. Nirsevimab is a monoclonal antibody made by AstraZeneca. Infants hospitalized with RSV often require oxygen support, intravenous fluids and are sometimes placed on a ventilator to support their breathing. There is another monoclonal antibody used against RSV called palivizumab. Nirsevimab is not considered a vaccine because it is a monoclonal antibody.
Persons: Infants, Biden, Palivizumab, Nirsevimab Organizations: Food and Drug Administration, FDA, AstraZeneca, Sanofi, Children Locations: U.S, Nirsevimab, United States, Canada, Europe, United Kingdom
☆ Explainer: COVID, flu and RSV this U.S. winter: Why experts are worried
  + stars: | 2022-10-26 | by ( Nancy Lapid | ) www.reuters.com   time to read: +3 min
REUTERS/Carlo Allegri/File PhotoOct 26 (Reuters) - U.S. doctors are warning that a surge in cases of respiratory syncytial virus (RSV) is coinciding with an increase in COVID transmission and an earlier-than-normal flu season, raising the specter of a "tripledemic" of respiratory illness this winter. In particular, RSV infections among young children are reportedly filling some U.S. hospitals to capacity. Older children and most adults typically experience mild, cold-like symptoms. In the meantime, it is important "for everyone to get up to date on their COVID and flu vaccines," Varma said. Part of the increase in RSV cases is due to the relaxation of COVID-precautions, such as masking and social distancing, which reduced rates of both RSV and flu during the pandemic, Varma said.
0 next >>
Total: 5